The availability of novel disease-modifying therapies (DMTs)—Copaxone 40 mg three times weekly (3TW), Plegridy, Lemtrada, oral DMTs—has complicated clinical decision-making and treatment choice in the management of multiple sclerosis (MS) in Europe. The syndicated ChartTrends: Multiple Sclerosis (EU) audit database and report allows clients to better understand the actual treatment of MS with DMTs through comparison of what physicians self-report about disease management with what actually occurs at the patient level in the clinical setting. Through an in-depth review of 1,006 charts from patients currently treated with Aubagio, Avonex, Betaferon, Copaxone (20 mg and 40 mg 3TW), Gilenya, Lemtrada, Plegridy, Rebif, Tecfidera, and Tysabri, details such as product initiation, switching, monitoring, anti-John Cunningham Virus (JCV) antibody assay testing, and a host of patient demographic variables, as well as reasons for initiation and discontinuation, help define patient types and identify drivers of therapy choice. The report also evaluates physician receptivity to late-phase emerging therapies for the treatment of MS and the potential introduction of generic glatiramer acetate 20 mg, and identifies potential characteristics of patient candidates for each therapy.